[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Oliva et al., 2016 - Google Patents

The 'omics' revolution: redefining the understanding and treatment of allergic skin diseases

Oliva et al., 2016

Document ID
970004514320739339
Author
Oliva M
Renert-Yuval Y
Guttman-Yassky E
Publication year
Publication venue
Current opinion in allergy and clinical immunology

External Links

Snippet

The ‘omics’ revolution: redefining the understanding and tre... : Current Opinion in Allergy and Clinical Immunology The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases : Current Opinion in Allergy and Clinical Immunology Log in or Register …
Continue reading at journals.lww.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means

Similar Documents

Publication Publication Date Title
Oliva et al. The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases
Zouboulis et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa
André et al. T cell apoptosis characterizes severe Covid-19 disease
Keiran et al. SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity
Brunner et al. Nonlesional atopic dermatitis skin shares similar T‐cell clones with lesional tissues
Schaller et al. Dual anti‐inflammatory and anti‐parasitic action of topical ivermectin 1% in papulopustular rosacea
Guttman-Yassky et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Renert-Yuval et al. What’s new in atopic dermatitis
Molin et al. The hand eczema proteome: imbalance of epidermal barrier proteins
da Rosa et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin
Wada et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis
Kim et al. Increased expression of the NLRP3 inflammasome components in patients with Behçet’s disease
Guenin-Macé et al. Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa
Bakker et al. Biomarkers in atopic dermatitis
Balato et al. Effects of adalimumab therapy in adult subjects with moderate‐to‐severe psoriasis on Th17 pathway
Politiek et al. Hyperkeratotic hand eczema: eczema or not?
Villani et al. Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response
Prieto-Perez et al. Pharmacogenetics of topical and systemic treatment of psoriasis
Curry et al. Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response
Hamann et al. First evidence for STING SNP R293Q being protective regarding obesity-associated cardiovascular disease in age-advanced subjects–a cohort study
Schmitz et al. Expression of CD64 on circulating neutrophils favoring systemic inflammatory status in erythema nodosum leprosum
Orfali et al. Staphylococcus aureus enterotoxins modulate IL-22-secreting cells in adults with atopic dermatitis
Tahaghoghi-Hajghorbani et al. Protective effect of TSLP and IL-33 cytokines in ulcerative colitis
Brandt et al. Exacerbation of allergen-induced eczema in TLR4-and TRIF-deficient mice
Pathinayake et al. Endoplasmic reticulum-unfolded protein response signalling is altered in severe eosinophilic and neutrophilic asthma